Clinical Trials Logo

Gastrointestinal Diseases clinical trials

View clinical trials related to Gastrointestinal Diseases.

Filter by:

NCT ID: NCT03342495 Completed - Stroke Clinical Trials

Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial

TNT
Start date: February 6, 2018
Phase: N/A
Study type: Interventional

The Transition Navigator Trial (TNT) is a pragmatic randomized controlled trial evaluating the effectiveness of usual care plus a patient navigator service versus usual care plus newsletters and other educational materials, to improve transition outcomes among adolescents aged 16-21 who have chronic health conditions requiring transfer to adult specialty care. The study will provide urgently needed data to guide health care providers and policy makers regarding the provision of coordinated transition care. These results have the potential to: 1. Change care delivery 2. Improve health outcomes 3. Improve the experiences of young adult transition to adult care

NCT ID: NCT03319446 Enrolling by invitation - Healthy Clinical Trials

Collection of Anonymized Samples

Start date: October 9, 2017
Phase: N/A
Study type: Observational

This is a generic sample collection study for collecting blood, stool, rectal swabs, nasal washes, nasopharyngeal aspirates, nasopharyngeal swabs, throat swabs, nasal swabs, and urine from human sources. Subjects will be recruited from BioFire Diagnostics employees and from the general community. Subjects may be asked about recent or ongoing illness at the time of specimen collection and these symptoms will be recorded and attached to the sample. No other identifying information will be collected and the samples will be kept anonymous.The samples may be used internally or by external sites, such as the clinical study sites, for evaluating and determining performance characteristics of in vitro diagnostic devices.

NCT ID: NCT03269617 Completed - Clinical trials for Gastrointestinal Disorder, Functional

PHAGE Study: Bacteriophages as Novel Prebiotics

Start date: October 1, 2016
Phase: N/A
Study type: Interventional

The PHAGE study is designed to determine if a commercial prebiotic product can change the composition of bacteria in the gut for improved intestinal health. A prebiotic is defined as an indigestible dietary component that selectively enhances specific bacterial species in the intestines to confer a health benefit. In this study, the prebiotic a unique combination of bacteriophages, or viruses that infect bacteria. These phages are generally regarded as safe for human consumption and work by infecting bad bacteria in the gut, which allows beneficial bacteria populations to increase. The product, PreforPro, has shown to be effective in culture-based and animal studies, but its efficacy has not been demonstrated in humans. The goal of this study is to see if PreforPro consumption improves gut bacteria profiles in individuals relative to a placebo control and is associated with reduced incidence and severity of gastrointestinal distress.

NCT ID: NCT03266315 Recruiting - Infant, Newborn Clinical Trials

Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery

ProPS
Start date: December 3, 2022
Phase: N/A
Study type: Interventional

Congenital defects of the gastrointestinal tract commonly require surgical intervention in the neonatal period. Intestinal surgery during this critical period of microbiome acquisition results in aberrant colonization of the gastrointestinal tract by several pathways. Surgical stress is known to cause disruption of the gut barrier and increase intestinal permeability and bacterial translocation. This process triggers exaggerated immune responses that lead to inflammation and sometimes infectious complications. Post-operative use of antibiotics has been shown to potentiate the growth of pathogenic bacterial species Adults with abdominal surgery who received post-op probiotics reported a significant reduction in surgical site infection, urinary tract infection, and combined infection. Currently, probiotics used only in the non-surgical population of infants. The main objective of this study is to determine the impact of probiotics administration on the intestinal microbiome in neonates undergoing intestinal surgery.

NCT ID: NCT03258216 Completed - Clinical trials for Upper Gastrointestinal Disorders

TCM Tongue Diagnosis Indices of UGI Disorders

Start date: January 1, 2016
Phase:
Study type: Observational

The Automatic Tongue Diagnosis System (ATDS) was developed to capture tongue images and extract features reliably to assist the diagnosis of TCM practitioners.This project will employ the ATDS verified to extract the tongue features of patients with upper gastrointestinal disorders, such as peptic ulcer, etc. A TCM indices derived through the non-intrusive tongue diagnosis procedure can provide valuable information for clinical doctors to analyze the current status of a patient and dynamically schedule a treatment plan, facilitating early detection and diagnosis of upper gastrointestinal disorders.

NCT ID: NCT03252743 Completed - Clinical trials for Irritable Bowel Syndrome

ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

This open trial aims to evaluate feasibility and preliminary effectiveness of an internet-delivered CBT-program for children and adolescents with functional gastrointestinal disorders when implemented in regular care.

NCT ID: NCT03234543 Enrolling by invitation - Liver Diseases Clinical Trials

Remote Ischemic Conditioning in Abdominal Surgery

Start date: October 8, 2017
Phase: N/A
Study type: Interventional

This phase II randomized (1:1) controlled trial will examine the effects of remote ischemic conditioning (RIC) on the outcomes of major abdominal surgery. One hundred subjects will be enrolled at a single institution - University Hospital - Newark. The study population are patients undergoing major abdominal surgery (anticipated to be >/= 2 hrs long with a hospital stay >/= 2 days). Subjects in the treatment group will receive lower limb ischemic conditioning at 3 different time points: before surgery, POD 1 and POD 2. The primary outcome is the 30-day comprehensive complications index (CCI). Key secondary outcomes are changes in systemic inflammatory markers in peripheral blood and 30-day mortality.

NCT ID: NCT03177044 Completed - Clinical trials for Inflammatory Bowel Diseases

Behavioural Treatment for Functional Bowel Symptoms in Inflammatory Bowel Disease

LIBERATE
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The primary aim of the project is to investigate whether a behavioural training programme improves troublesome bowel symptoms, that people with inflammatory bowel disease continue to have, despite their disease being controlled by medication. The other aim is to determine if there are factors which influence how well the training programme works. People attending an Inflammatory Bowel Disease clinic in a tertiary hospital, with bothersome bowel symptoms despite disease control, will be asked to join the study. This involves 2 to 6 sessions with a pelvic floor trained physiotherapist over a period of 6 months with further follow up at 12 months..

NCT ID: NCT03166007 Completed - Multiple Sclerosis Clinical Trials

Abdominal Massage for Bowel Dysfunction

AMBER
Start date: June 2014
Phase: N/A
Study type: Interventional

The aim of the AMBER trial is to determine the effectiveness and cost effectiveness of abdominal massage as part of the adjunct to bowel care in people with Multiple Sclerosis who have problems with their bowel i.e. faecal incontinence and/or constipation.

NCT ID: NCT03150212 Completed - Clinical trials for Constipation-predominant Irritable Bowel Syndrome

Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype

IBS-GO
Start date: March 20, 2017
Phase: N/A
Study type: Interventional

The main objective is to assess the effect of an 8-week daily supplementation with IbSium® (probiotic yeast Saccharomyces cerevisiae CNCM I-3856) on the improvement gastro-intestinal disorders associated to the type C IBS (constipation predominant).